Tempest Therapeutics Inc.

NASDAQ: TPST · Real-Time Price · USD
10.71
1.23 (12.97%)
At close: Aug 15, 2025, 1:09 PM

Tempest Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
389K 381K n/a n/a
Gross Profit
-389K -381K -1.81M -1.27M
Operating Income
-42.03M -29.16M -34.64M -26.99M
Interest Income
1.5M 1.11M 549K 1.28K
Pretax Income
-41.84M -29.49M -35.71M -28.3M
Net Income
-41.84M -29.49M -35.71M -28.3M
Selling & General & Admin
13.55M 11.66M 12.11M 9.82M
Research & Development
28.48M 17.5M 22.53M 17.17M
Other Expenses
-389K n/a n/a -34K
Operating Expenses
41.64M 28.78M 34.64M 26.99M
Interest Expense
1.32M 1.45M 1.62M 1.28M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
42.03M 29.16M 34.64M 26.99M
Income Tax Expense
n/a n/a n/a n/a
Shares Outstanding (Basic)
27.9M 15.42M 888K 291K
Shares Outstanding (Diluted)
27.9M 15.42M 888.38K 291.56K
EPS (Basic)
-1.5 -1.91 -3.18 -7.8
EPS (Diluted)
-1.5 -1.91 -3.18 -7.8
EBITDA
-40.14M -28.78M -32.28M -25.72M
EBIT
-40.53M -29.16M -34.09M -26.99M
Depreciation & Amortization
389K 381K 1.81M 1.27M